Ovarian Cancer Pipeline Review: Sponsors Plan Frontline Punch, Smart Combinations
Executive Summary
Combination studies of drugs for ovarian cancer have heavy focus on PARP, PD-1/L1 and VEGF mechanisms.
You may also be interested in...
ImmunoGen Needs Another Phase III For Its ADC In Ovarian Cancer
The biotech’s hopes for an accelerated approval on subgroup data were dashed by the US FDA, but it will work with the agency to design a Phase III focused on highly FRα-positive patients.
Tesaro's On The Right Path With Anti-PD-1 Dostarlimab In Endometrial Cancer
Interview: Tesaro Chief Medical Officer Martin Huber addresses dostarlimab GARNET data and provides an update on integration with GlaxoSmithKline.
Clinical Trials In Review: Big Hits And Misses In 2018
Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.